Abstract:Gankyrin is a 25 kDa oncoprotein that plays a crucial role in cellular growth, proliferation, and migration. It is highly conserved and has 7 ankyrin repeats which bind to the S6 ATPase subunit of the 26S proteasome. It has been shown that gankyrin exerts its oncogenic activities by interacting with numerous tumor suppressor proteins (TSPs) such as p53 and retinoblastoma protein (Rb), which in turn promotes their proteasomal degradation. While Rb plays an important role in cell adhesion, p53 inhibits Rac/CDC42 which is responsible for lamellipodia and filopodia formation. Gankyrin is also reported to increase the levels of interleukin‐6 (IL‐6) which activates the JAK/STAT3 pathway. The phosphorylation of STAT3 to p‐STAT3 and the subsequent nuclear translocation of p‐STAT3 results in transcription of migratory factors. The inhibition of these gankyrin‐based protein‐protein interactions (PPI) by a small molecule inhibitor, should result in an anti‐migratory effect. Cjoc42 is the first known binder of gankyrin, and since its discovery we have developed two derivatives with an enhanced ability to bind gankyrin, – AFM‐2 and JA‐38 In order to determine if next‐generation gankyrin inhibitors could affect cancer cell migration, we evaluated both compounds in gankyrin overexpressing cell lines A549 and MDA‐MB‐231. Their ability to disrupt multiple gankyrin‐based PPIs is hypothesized to be due to their ability to induce a conformational change in gankyrin upon binding. Various assays such as the scratch assay, Boyden chamber assay, western blotting, co‐immunoprecipitation (co‐IP) assay and fluorescence‐based assays were used to evaluate our hypotheses. We evaluated the anti‐migratory potential of the molecules by scratch and Boyden chamber assay. The molecules’ ability to disrupt gankyrin’s interactions with p53, Rb and the S6 proteasome was evaluated by co‐IP assay. Using western blotting, we evaluated the changes in the levels of various TSPs and migratory proteins upon treatment with the molecules. To test our hypothesis of induction of conformational change in gankyrin upon treatment with the molecules, we utilized florescence‐based experiments such as intrinsic fluorescence evaluation and thermal shift. The cell‐based scratch and Boyden chamber assay showed significant decreases in cellular migration in both cell lines upon treatment with the molecules. Co‐IP experiments demonstrated that both molecules disrupt various gankyrin‐based PPIs. Disruption of gankyrin’s interactions with the TSPs would prevent their subsequent proteasomal degradation and subsequently affect the levels of downstream proteins such as IL‐6 and Rac/CDC42. Significant reduction in the migratory proteins and a significant increase in the TSPs was confirmed by western blotting. Lastly, using fluorescence‐based experiments, we believe that the binding of the two molecules caused a conformation change in gankyrin, which could be why gankyrin’s multiple PPIs are disrupted. Gankyrin plays a key role controlling cellular migratory pathways through its various PPIs. By inducing a conformational change in gankyrin, our molecules disrupt these PPI and exhibit significant anti‐migratory activity which could prevent cancer metastasis.

Arp2/3 complex inhibitors adversely affect actin cytoskeleton remodeling in the cultured murine kidney collecting duct M-1 cells

CK-666 and CK-869 differentially inhibit Arp2/3 iso-complexes

Differential interference with actin-binding protein function by acute Cytochalasin B

Effect of inhibiting cytoskeleton on the mechanical properties of normal rat kidney cells

Lateral distribution of phosphatidylinositol 4,5-bisphosphate in membranes regulates formin- and ARP2/3-mediated actin nucleation

Vinculin-Arp2/3 interaction inhibits branched actin assembly to control migration and proliferation

Arp2/3 complex-dependent actin regulation protects the survival of tissue-resident mast cells

New targets and designed inhibitors of ASAP Arf-GAPs derived from structural characterization of the ASAP1/440-kD ankyrin-B interaction

Arp2/3-Branched Actin Maintains an Active Pool of GTP-RhoA and Controls RhoA Abundance

Arp2/3-Branched Actin Maintains an Active Pool of GTP-RhoA and Controls RhoA Abundance.

Exploiting the Cellular Actions of Skca and Ikca Channels to Manipulate Endothelial Function and Vascular Tone

Comprehensive cell biological investigation of cytochalasin B derivatives with distinct activities on the actin network

Expression Of The Arp2/3 Complex In Human Gliomas And Its Role In The Migration And Invasion Of Glioma Cells

Myosin Light Chain Kinase / Actin Interaction in Phorbol Dibutyrate–Stimulated Smooth Muscle Cells

Loss of Arp2/3 Induces an NF-κB–dependent, Nonautonomous Effect on Chemotactic Signaling

Arp2/3-branched actin regulates microtubule acetylation levels and affects mitochondrial distribution

Evaluation of the Anti‐Migratory Activity of Small‐molecule Gankyrin Inhibitors in A549 and MDA‐MB‐231 Cells

ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma

Arp2/3 Complex Regulates Asymmetric Division and Cytokinesis in Mouse Oocytes.

Arp2/3-Branched Actin Regulates Microtubule Acetylation Level And Affects Mitochondria Distribution.